Lipid Metabolism – Medxy AI

Six Months of Intermittent Fasting: Potent Lipid Lowering but Limited Impact on Vascular and Glycemic Markers

By MedXY 01/20/2026

A randomized controlled trial investigates the 6-month effects of intermittent fasting on overweight adults, revealing significant improvements in lipid profiles and body composition despite neutral effects on blood pressure and glucose metabolism, alongside novel transcriptomic insights into GLP-1 signaling.

Hematology-Oncology news

Metformin Triggers Ferroptosis in AML Through Lipid Remodeling: A Repurposing Opportunity for Metabolic Subtypes

By MedXY 11/23/2025

A new ex vivo study shows metformin induces ROS-driven ferroptosis in acute myeloid leukemia (AML), particularly in samples with altered lipid metabolism (IDH2, FLT3 mutations). Lipidomic remodeling, CD36-mediated fatty acid uptake, and DGAT1 activity determine sensitivity—suggesting biomarker-guided repurposing strategies and combination approaches.

Gastroenterology news Oncology

Exceptional Efficacy of Olverembatinib in a Subtype of Gastrointestinal Stromal Tumors with Marked Improvement in Progression-Free Survival

By MedXY 11/05/2025

Olverembatinib showed outstanding efficacy in treating succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST), significantly extending median progression-free survival to 25.7 months compared to traditional therapies.

news Oncology

Alcohol’s Amplifying Effect on HBV-Related Liver Cancer: New Insights into Metabolic Reprogramming

By MedXY 10/27/2025

This article explores how alcohol consumption worsens HBV-induced hepatocellular carcinoma by promoting ER stress and lipid metabolic disturbances, highlighting potential therapeutic targets like LPLA2 and BMP.